The View on GU | with Lalani and Wallis

With new bladder cancer therapies on the horizon, Dr. Lalani and Dr. Wallis review promising trial results - including EVER, CREST and the CISTO Study -presented at this year's annual meeting. They also address key practical challenges for bladder cancer treatment, from both a medical oncologist and a urologic oncologist's perspective.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Novartis, Bayer, Astellas, Tolmar, J&J, Merck, Pfizer, Eisai and AbbVie.

In this informative episode, Dr. Aly-Khan Lalani and Dr. Christopher Wallis are joined by Dr. Frédéric Pouilot, a urologist-oncologist and researcher in molecular imaging at the CHU de Québec-Université Laval Research Center. Together, they unpack the evolving role of PSMA PET in prostate cancer and how advanced imaging tools are reshaping treatment decisions. The conversation also looks ahead, to the future of dynamic imaging, and its potential to revolutionize personalized cancer care.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Novartis, Bayer, Astellas, Tolmar, J&J, Merck, Pfizer, Eisai and AbbVie.

In this must-listen episode, your hosts are joined by Dr. Zukotynski, a Professor of Medicine and Radiology at McMaster University and staff member at Hamilton Health Sciences. With her expertise in nuclear medicine and radiology, she delves into treatment logistics, the essential role of multidisciplinary coordination, and more.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Novartis, Bayer, Astellas, Tolmar, J&J, Merck, Pfizer, Eisai and AbbVie.

Episode 19 is the final part of a mini-series from the 2025 ASCO Genitourinary Cancers Symposium in San Francisco! After diving into prostate and bladder cancers in the first two episodes, Dr. Aly-Khan Lalani and Dr. Christopher Wallis are wrapping with an in-depth look at kidney cancer, diving into research, studies and developments shared at the symposium. The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take-home messages for practicing clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Bayer, Astellas, J&J, Tolmar, Merck, and Pfizer.

Dr. Aly-Khan Lalani and Dr. Christopher Wallis reflect on the 2025 ASCO Genitourinary Cancers Symposium, with a focus on bladder cancer. This is the second part of a three-episode series filmed live in San Francisco.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take-home messages for practicing clinicians in the field of genitourinary (GU) cancers. This podcast has been made possible through unrestricted financial support by Bayer, Astellas, J&J, Tolmar, Merck, and Pfizer.

Dr. Aly-Khan Lalani and Dr. Christopher Wallis discuss new findings, novel treatment approaches, and research surrounding prostate cancer from their time at the 2025 ASCO GU Symposium. This can't-miss special is the first of three episodes recorded live from San Francisco!The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take-home messages for practicing clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Bayer, Astellas, J&J, Tolmar, Merck, and Pfizer.

Wrapping up their ESMO Congress 2024 coverage with a discussion of renal cancer, our hosts talk about what strategies work (or don't) after frontline therapy for mRCC, implications on adjuvant therapy, as well as major efforts for non-clear cell histologies like the SUNNIFORECAST trial. The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca This podcast has been made possible through unrestricted financial support by Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsen, J&J Innovative Medicine, Merck, Novartis, Pfizer, TerSera.

In the second episode of our ESMO Congress 2024 series, our hosts discuss both non-muscle invasive and muscle-invasive bladder cancer, along with other data that impacts the spectrum of urothelial cancer diagnosis and treatment.  The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca This podcast has been made possible through unrestricted financial support by Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsen, J&J Innovative Medicine, Merck, Novartis, Pfizer, TerSera.

In the first episode of this three-part series focused on the presentations and findings from the ESMO Congress 2024, our hosts focus on mCSPC prostate cancer treatment advancements, including lutetium PSMA, darolutamide and much more. The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca This podcast has been made possible through unrestricted financial support by Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsen, J&J Innovative Medicine, Merck, Novartis, Pfizer, TerSera.

Building on Episode 12, which focused on primary treatment for prostate cancer, Drs. Loblaw, Lalani and Wallis move on to discuss post-op treatments, including the evolution of post-operative radiotherapy and the shift from adjuvant therapy to early salvage therapy.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: https://theviewongu.com This podcast has been made possible through unrestricted financial support by Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsen, Merck, Novartis, Pfizer and TerSera

Dr. Andrew Loblaw (Radiation Oncologist (Sunnybrook Research Institute), Clinician Scientist, and dual Professor in the Department of Radiation Oncology and the Institute of Health Policy Management & Evaluation at the University of Toronto) takes time out of the busy 2024 Canadian Urological Association Annual Meeting schedule to chat with Dr. Aly-Khan Lalani and Dr. Christopher Wallis. Dr. Loblaw provides an overview of how he treats his patients, including shifting to hypofractionation, brachytherapy boosts and more. Keep an eye out for Episode 13, which is the second and final part of this mini-series! This podcast has been made possible through unrestricted financial support by Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsen, Merck, Novartis, Pfizer and TerSera. The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: https://theviewongu.com

Dr. Lalani and Dr. Wallis cover the utility of metformin, quality of life analyses, and optimizing treatment approaches for resistant prostate cancer, including the place for radioligand therapies.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practicing clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: https://theviewongu.com This podcast has been made possible through financial support by Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsen, Merck, Novartis, Pfizer and TerSera.

Our hosts start by discussing the 901 trial before moving into a discussion about bladder preservation and the importance of being multi-disciplinary.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practicing clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: https://theviewongu.com This podcast has been made possible through financial support by Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsen, Merck, Novartis, Pfizer and TerSera.

The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practicing clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: https://theviewongu.com This podcast has been made possible through financial support by Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsen, Merck, Novartis, Pfizer and TerSera.

Joined by MD Anderson Cancer Center clinician and scientist Dr. Pavlos Msaouel, Dr. Aly-Khan Lalani and Dr. Christopher Wallis discuss trial design and statistics in oncology. What are the nuances to reading KM curves? How useful are forest plots? Our guest and hosts dive into this and more in Episode 8. The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practicing clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: https://theviewongu.com This podcast has been made possible through financial support by AstraZeneca, Bristol Myers Squibb, Merck, and TerSera.

Episode 7 was filmed live in Niagara, Ontario at the 13th Annual Juravinski Cancer Centre and Walker Cancer Centre Uro-oncology Forum! Our hosts discuss Dr. Christopher Wallis' presentation about physician and surgeon gender and how it impacts patient care, surgical outcomes, mortality and more - especially in the field of genitourinary cancers. The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practicing clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: https://theviewongu.com This podcast has been made possible through financial support by AstraZeneca, Bristol Myers Squibb, Merck, and TerSera.

In Episode 6, Drs. Aly-Khan Lalani and Christopher Wallis are joined by The View on GU's first guest Dr. Diana Magee to discuss why location matters when it comes to medical conferences. They touch upon Dr. Magee's recent article in The Journal of Urology, and consider the ethical, economic and political implications of the upcoming American Urological Association conference in Texas following implementation of the state's abortion ban. The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practicing clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: https://theviewongu.com This podcast has been made possible through financial support by Bristol Myers Squibb, Merck, and TerSera. The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of hospital corporations and are not intended to be personal medical advice.

In Episode 5, Drs. Aly-Khan Lalani and Christopher Wallis discuss biochemical recurrence in prostate cancer, including what they're seeing in the field right now in terms of treatment options, what physicians should know moving forward and multi-D care for patients. The doctors also provide an overview of the recent EMBARK trial, noting efficacy outcomes and key learnings. The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practicing clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: https://theviewongu.com This podcast has been made possible through financial support by Bristol Myers Squibb, Merck, and TerSera.

After returning from the 2024 ASCO Genitourinary Cancers Symposium in San Francisco, our hosts Drs. Aly-Khan Lalani and Christopher Wallis share key takeaways for clinical practice and their thoughts on high impact presentations about prostate, kidney, and bladder cancers, expanding on their discussions from Episodes 1-3. The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practicing clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: https://theviewongu.com/  This podcast has been made possible through financial support by Bristol Myers Squibb, Merck, and TerSera.

Filmed live at #GU24, episode 3 of The View on GU features a discussion on survival data with adjuvant therapy for patients with resected kidney cancer, as well as long-term followup for those with metastatic disease. The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications into meaningful take home messages for practicing clinicians in the field of genitourinary (GU) cancers. Filmed live at the 2024 ASCO Genitourinary Cancers Symposium, Drs. Aly-Khan Lalani and Christopher Wallis discuss survival outcomes for adjuvant therapy, and exciting updated datasets in episode 3. Learn more about The View on GU: theviewongu.com This podcast has been made possible through financial support by Bristol Myers Squibb, Merck, and TerSera.

Filmed live at #GU24, episode 2 of The View on GU examines late breaking data for patients with urothelial carcinoma. The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications into meaningful take home messages for practicing clinicians in the field of genitourinary (GU) cancers. Filmed live at the 2024 ASCO Genitourinary Cancers Symposium, Drs. Aly-Khan Lalani and Christopher Wallis examine new and updated data, and recent achievements in urothelial carcinoma research. Learn more about The View on GU: theviewongu.com This podcast has been made possible through financial support by Bristol Myers Squibb, Merck, and TerSera.

Filmed live at #GU24, episode 1 of The View on GU dives into new and updated data and novel treatment approaches for patients with prostate cancer. The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications into meaningful take home messages for practicing clinicians in the field of genitourinary (GU) cancers. Filmed live at the 2024 ASCO Genitourinary Cancers Symposium in San Francisco, Drs. Aly-Khan Lalani and Christopher Wallis discuss new and updated data and integrate what these trials mean for practicing clinicians. Learn more about The View on GU: theviewongu.com This podcast has been made possible through financial support by Bristol Myers Squibb, Merck, and TerSera.

A new podcast developed by clinicians for clinicians, focused on optimizing multi-disciplinary healthcare within the field of genitourinary cancers. This podcast has been made possible through financial support by Bristol Myers Squibb, Merck, and TerSera.